Summary
- Current Price
- As of today, CYTK price is $71.48, down -1.12% on
- Current Price All-Time High
- CYTK price is currently -35.17% below its historical high of $110.25 set on
- Market Cap
- CYTK current market cap is $10B, up +153.75% over the past 365 days
- PE Ratio
- CYTK PE ratio is unknown
- Revenue
- CYTK current annual revenue is $88.04M, up +376.56% year-over-year
- Next Earnings
- The next earnings release for CYTK is on
Profile
| Metric | Value |
|---|---|
| Full Name | Cytokinetics, Incorporated |
| Ticker | NASDAQ: CYTK |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | cytokinetics.com |
| Employees | 498 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $71.48 | |
| Price, 1D Change | -1.12% | |
| Market Cap | $10B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.82 | |
| Revenue | $88M | |
| Revenue, 1Y Change | +376.56% | |
| EPS | -$6.54 | |
| EPS, 1Y Change | -24.14% |
Chart
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 1:6 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$6.54 | |
| EPS Estimate | N/A | -$6.43 |
| EPS Est. Change | N/A | +1.55% |
| Revenue | $88.04M | |
| Revenue Estimate | N/A | $109.27M |
| Revenue Est. Change | N/A | +24.12% |
| Current Price | $71.48 | |
| Price Target | - | $104.00 |
| Price Tgt. Change | - | +45.50% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.16 | -$5.26 | -1.98% | |
| -$6.22 | -$6.54 | -5.04% | |
| -$6.43 | N/A | +1.55% | |
| -$4.75 | N/A | +27.26% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $14.37M | $18.47M | +28.55% | |
| $81.03M | $88.04M | +8.65% | |
| $109.27M | N/A | +24.12% | |
| $387.38M | N/A | +340.01% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +122.82% | |
| Price, 3Y | +88.11% | |
| Market Cap, 1Y | +153.75% | |
| Market Cap, 3Y | +167.12% | |
| Revenue, 1Y | +376.56% | |
| Revenue, 3Y | -6.92% | |
| EPS, 1Y | -24.14% | |
| EPS, 3Y | -50.94% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Date | Value |
|---|---|---|
| Current Price | $71.48 | |
| SMA 200 | $62.23 | |
| SMA 50 | $69.69 | |
| EMA 200 | $62.11 | |
| EMA 50 | $70.64 | |
| MACD | $0.90 | |
| Beta | 0.82 | |
| ATR | $2.95 | |
| 14-Day RSI | 42.31 | |
| 10-Day Volatility | 30.57% | |
| 1-Year Volatility | 61.05% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $88.04M | |
| EPS | -$6.54 | |
| Gross Profit | $0.00 | |
| Gross Margin | 88.50% | |
| Operating Income | -$612.26M | |
| Operating Margin | -695.44% | |
| Net Income | -$784.96M | |
| Net Margin | -891.60% | |
| EBITDA | -$602.13M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | -1.95 | |
| 4.53 | ||
| 4.53 | ||
| - | ||
| 3 | ||
| -1.39 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| 91.72 | ||
| -11.74 | ||
| -16.17 | ||
| N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | -$659.62M | |
| $885.34M | ||
| $1.42B | ||
| $916.98M | ||
| $2.08B | ||
| $202.45M | ||
| Total Debt | $1.28B | |
| $60.29M | ||
| $22.34M |
Expenses
| Metric | Date | Value |
|---|---|---|
| $872.99M | ||
| $612.26M | ||
| $10.13M | ||
| $0.00 | ||
| $10.13M | ||
| $0.00 | ||
| $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| -$510.01M | ||
| $16.67M | ||
| $524.46M | ||
| Capex | $24.81M | |
| -$534.82M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Citigroup | ||
| JP Morgan | → | |
| HC Wainwright & Co. | → | |
| Wells Fargo | → | |
| Stifel | → | |
| RBC Capital | → | |
| Morgan Stanley | → | |
| Needham | → | |
| Wells Fargo | ||
| Barclays | → |
Analyst sentiment
Institutional ownership
Screeners with CYTK
FAQ
What is the ticker symbol for Cytokinetics, Incorporated?
The ticker symbol for Cytokinetics, Incorporated is NASDAQ:CYTK
Does Cytokinetics, Incorporated pay dividends?
No, Cytokinetics, Incorporated does not pay dividends
What sector is Cytokinetics, Incorporated in?
Cytokinetics, Incorporated is in the Healthcare sector
What industry is Cytokinetics, Incorporated in?
Cytokinetics, Incorporated is in the Biotechnology industry
What country is Cytokinetics, Incorporated based in?
Cytokinetics, Incorporated is headquartered in United States
When did Cytokinetics, Incorporated go public?
Cytokinetics, Incorporated initial public offering (IPO) was on April 30, 2004
Is Cytokinetics, Incorporated in the S&P 500?
No, Cytokinetics, Incorporated is not included in the S&P 500 index
Is Cytokinetics, Incorporated in the NASDAQ 100?
No, Cytokinetics, Incorporated is not included in the NASDAQ 100 index
Is Cytokinetics, Incorporated in the Dow Jones?
No, Cytokinetics, Incorporated is not included in the Dow Jones index
When was Cytokinetics, Incorporated last earnings report?
Cytokinetics, Incorporated's most recent earnings report was on May 5, 2026
When does Cytokinetics, Incorporated report earnings?
The next expected earnings date for Cytokinetics, Incorporated is August 6, 2026
Data Sources & References
- CYTK Official Website www.cytokinetics.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.htm
- CYTK Profile on Yahoo Finance finance.yahoo.com/quote/CYTK
- CYTK Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/cytk